192 related articles for article (PubMed ID: 9502775)
1. Glucagon-like peptide-1 stimulates luteinizing hormone-releasing hormone secretion in a rodent hypothalamic neuronal cell line.
Beak SA; Heath MM; Small CJ; Morgan DG; Ghatei MA; Taylor AD; Buckingham JC; Bloom SR; Smith DM
J Clin Invest; 1998 Mar; 101(6):1334-41. PubMed ID: 9502775
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes.
Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM
Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327
[TBL] [Abstract][Full Text] [Related]
3. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat.
Larsen PJ; Tang-Christensen M; Jessop DS
Endocrinology; 1997 Oct; 138(10):4445-55. PubMed ID: 9322962
[TBL] [Abstract][Full Text] [Related]
4. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus.
Owji AA; Khoshdel Z; Sanea F; Panjehshahin MR; Shojaee Fard M; Smith DM; Coppock HA; Ghatei MA; Bloom SR
Brain Res; 2002 Mar; 929(1):70-5. PubMed ID: 11852032
[TBL] [Abstract][Full Text] [Related]
5. Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction.
Fehmann HC; Bode HP; Ebert T; Karl A; Göke B
Horm Metab Res; 1997 Nov; 29(11):572-6. PubMed ID: 9479558
[TBL] [Abstract][Full Text] [Related]
6. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
Perry T; Haughey NJ; Mattson MP; Egan JM; Greig NH
J Pharmacol Exp Ther; 2002 Sep; 302(3):881-8. PubMed ID: 12183643
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes.
Vila Petroff MG; Egan JM; Wang X; Sollott SJ
Circ Res; 2001 Aug; 89(5):445-52. PubMed ID: 11532906
[TBL] [Abstract][Full Text] [Related]
8. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling.
Heller RS; Kieffer TJ; Habener JF
Biochem Biophys Res Commun; 1996 Jun; 223(3):624-32. PubMed ID: 8687446
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 (GLP-1) releases thyrotropin (TSH): characterization of binding sites for GLP-1 on alpha-TSH cells.
Beak SA; Small CJ; Ilovaiskaia I; Hurley JD; Ghatei MA; Bloom SR; Smith DM
Endocrinology; 1996 Oct; 137(10):4130-8. PubMed ID: 8828468
[TBL] [Abstract][Full Text] [Related]
10. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH
J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804
[TBL] [Abstract][Full Text] [Related]
11. Neuropeptide Y stimulates luteinizing hormone-releasing hormone release from superfused hypothalamic GT1-7 cells.
Besecke LM; Wolfe AM; Pierce ME; Takahashi JS; Levine JE
Endocrinology; 1994 Oct; 135(4):1621-7. PubMed ID: 7925125
[TBL] [Abstract][Full Text] [Related]
12. The peptide-hormone glucagon-like peptide-1 activates cAMP and inhibits growth of breast cancer cells.
Ligumsky H; Wolf I; Israeli S; Haimsohn M; Ferber S; Karasik A; Kaufman B; Rubinek T
Breast Cancer Res Treat; 2012 Apr; 132(2):449-61. PubMed ID: 21638053
[TBL] [Abstract][Full Text] [Related]
13. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes.
Montrose-Rafizadeh C; Yang H; Wang Y; Roth J; Montrose MH; Adams LG
J Cell Physiol; 1997 Sep; 172(3):275-83. PubMed ID: 9284947
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of platelet-activating factor (PAF) on luteinizing hormone-releasing hormone and somatostatin release from rat median eminence in vitro correlated with the characterization of specific PAF receptor sites in rat hypothalamus.
Junier MP; Tiberghien C; Rougeot C; Fafeur V; Dray F
Endocrinology; 1988 Jul; 123(1):72-80. PubMed ID: 2898362
[TBL] [Abstract][Full Text] [Related]
15. Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: lack of coupling to either stimulation or inhibition of adenylyl cyclase.
Satoh F; Beak SA; Small CJ; Falzon M; Ghatei MA; Bloom SR; Smith DM
Endocrinology; 2000 Apr; 141(4):1301-9. PubMed ID: 10746632
[TBL] [Abstract][Full Text] [Related]
16. Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations.
Greig NH; Holloway HW; De Ore KA; Jani D; Wang Y; Zhou J; Garant MJ; Egan JM
Diabetologia; 1999 Jan; 42(1):45-50. PubMed ID: 10027577
[TBL] [Abstract][Full Text] [Related]
17. Effects of glucagon-like peptide-1 (GLP-1) in RINm5F insulinoma cells. Stimulation of insulin secretion, insulin content, and insulin receptor binding.
Jehle PM; Jehle D; Fussgänger RD; Adler G
Exp Clin Endocrinol Diabetes; 1995; 103 Suppl 2():31-6. PubMed ID: 8839251
[TBL] [Abstract][Full Text] [Related]
18. Rat parietal cell receptors for GLP-1-(7-36) amide: northern blot, cross-linking, and radioligand binding.
Schmidtler J; Dehne K; Allescher HD; Schusdziarra V; Classen M; Holst JJ; Polack A; Schepp W
Am J Physiol; 1994 Sep; 267(3 Pt 1):G423-32. PubMed ID: 7943240
[TBL] [Abstract][Full Text] [Related]
19. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4.
Raufman JP; Singh L; Singh G; Eng J
J Biol Chem; 1992 Oct; 267(30):21432-7. PubMed ID: 1328231
[TBL] [Abstract][Full Text] [Related]
20. Prolactin releasing peptide (PrRP) stimulates luteinizing hormone (LH) and follicle stimulating hormone (FSH) via a hypothalamic mechanism in male rats.
Seal LJ; Small CJ; Kim MS; Stanley SA; Taheri S; Ghatei MA; Bloom SR
Endocrinology; 2000 May; 141(5):1909-12. PubMed ID: 10803604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
